107 related articles for article (PubMed ID: 28498452)
1. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
Liu L; Lou N; Li X; Xu G; Ruan H; Xiao W; Qiu B; Bao L; Yuan C; Huang X; Wang K; Cao Q; Chen K; Yang H; Zhang X
Oncol Rep; 2017 Jun; 37(6):3651-3659. PubMed ID: 28498452
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents.
Zhang G; Liu X; Li J; Ledet E; Alvarez X; Qi Y; Fu X; Sartor O; Dong Y; Zhang H
Oncotarget; 2015 Sep; 6(27):23358-71. PubMed ID: 26160840
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment.
Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM
Neoplasia; 2020 Feb; 22(2):111-119. PubMed ID: 31931431
[TBL] [Abstract][Full Text] [Related]
4. Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer.
Luo J
Asian J Androl; 2016; 18(4):580-5. PubMed ID: 27174161
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.
Cao B; Qi Y; Zhang G; Xu D; Zhan Y; Alvarez X; Guo Z; Fu X; Plymate SR; Sartor O; Zhang H; Dong Y
Oncotarget; 2014 Mar; 5(6):1646-56. PubMed ID: 24722067
[TBL] [Abstract][Full Text] [Related]
6. SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain.
Yi Q; Han X; Yu HG; Chen HY; Qiu D; Su J; Lin R; Batist G; Wu JH
Oncogene; 2024 May; 43(20):1522-1533. PubMed ID: 38532114
[TBL] [Abstract][Full Text] [Related]
7. Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance.
Zhan Y; Zhang G; Wang X; Qi Y; Bai S; Li D; Ma T; Sartor O; Flemington EK; Zhang H; Lee P; Dong Y
Mol Cancer Res; 2017 Jan; 15(1):59-68. PubMed ID: 27671337
[TBL] [Abstract][Full Text] [Related]
8. ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.
Cai L; Tsai YH; Wang P; Wang J; Li D; Fan H; Zhao Y; Bareja R; Lu R; Wilson EM; Sboner A; Whang YE; Zheng D; Parker JS; Earp HS; Wang GG
Mol Cell; 2018 Oct; 72(2):341-354.e6. PubMed ID: 30270106
[TBL] [Abstract][Full Text] [Related]
9. AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer.
Kim S; Au CC; Jamalruddin MAB; Abou-Ghali NE; Mukhtar E; Portella L; Berger A; Worroll D; Vatsa P; Rickman DS; Nanus DM; Giannakakou P
Elife; 2022 Jul; 11():. PubMed ID: 35848798
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor variant-7 regulation by tenascin-c induced src activation.
Thomas R; Jerome JM; Dang TD; Souto EP; Mallam JN; Rowley DR
Cell Commun Signal; 2022 Aug; 20(1):119. PubMed ID: 35948987
[TBL] [Abstract][Full Text] [Related]
11. AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption.
Sobhani N; Neeli PK; D'Angelo A; Pittacolo M; Sirico M; Galli IC; Roviello G; Nesi G
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073713
[TBL] [Abstract][Full Text] [Related]
12. Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.
Kwegyir-Afful AK; Ramalingam S; Purushottamachar P; Ramamurthy VP; Njar VC
Oncotarget; 2015 Sep; 6(29):27440-60. PubMed ID: 26196320
[TBL] [Abstract][Full Text] [Related]
13. AR-V7 expression facilitates accelerated G2/M phase transition in castration-resistant prostate cancer.
Saini T; Gupta P; Raut R; Nayak V; Bharathnaveen P; Mishra P; Misra A
Exp Cell Res; 2024 May; 438(1):114026. PubMed ID: 38604522
[TBL] [Abstract][Full Text] [Related]
14. NanoLuc Binary Technology as a methodological approach: an important new tool for studying the localization of androgen receptor and androgen receptor splice variant V7 homo and heterodimers.
Guzman J; Weigelt K; Neumann A; Tripal P; Schmid B; Winter Z; Palmisano R; Culig Z; Cronauer MV; Muschler P; Wullich B; Taubert H; Wach S
BMC Cancer; 2024 Mar; 24(1):346. PubMed ID: 38500100
[TBL] [Abstract][Full Text] [Related]
15. Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
Yang JC; Xu P; Ning S; Wasielewski LJ; Adomat H; Hwang SH; Morisseau C; Gleave M; Corey E; Gao AC; Lara PN; Evans CP; Hammock BD; Liu C
Oncogene; 2023 Feb; 42(9):693-707. PubMed ID: 36596844
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.
Kahn B; Collazo J; Kyprianou N
Int J Biol Sci; 2014; 10(6):588-95. PubMed ID: 24948871
[TBL] [Abstract][Full Text] [Related]
17. A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformation.
Wang J; Park KS; Yu X; Gong W; Earp HS; Wang GG; Jin J; Cai L
Nucleic Acids Res; 2022 Oct; 50(19):10929-10946. PubMed ID: 36300627
[TBL] [Abstract][Full Text] [Related]
18. Marine compound rhizochalinin shows high in vitro and in vivo efficacy in castration resistant prostate cancer.
Dyshlovoy SA; Otte K; Alsdorf WH; Hauschild J; Lange T; Venz S; Bauer CK; Bähring R; Amann K; Mandanchi R; Schumacher U; Schröder-Schwarz J; Makarieva TN; Guzii AG; Tabakmakher KM; Fedorov SN; Shubina LK; Kasheverov IE; Ehmke H; Steuber T; Stonik VA; Bokemeyer C; Honecker F; von Amsberg G
Oncotarget; 2016 Oct; 7(43):69703-69717. PubMed ID: 27626485
[TBL] [Abstract][Full Text] [Related]
19. Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer.
Qu Y; Dai B; Ye D; Kong Y; Chang K; Jia Z; Yang X; Zhang H; Zhu Y; Shi G
Sci Rep; 2015 Jan; 5():7654. PubMed ID: 25563505
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?
Leibrand CR; Price DK; Figg WD
Cancer Biol Ther; 2016 May; 17(5):467-9. PubMed ID: 26985596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]